Business Wire

WA-AMAZON.COM

3.11.2022 12:09:44 CET | Business Wire | Press release

Share
Amazon and USAID Launch Effort to Boost Climate Funding for Women

Amazon and the U.S. Agency for International Development (USAID) are launching a public-private partnership to address the gender inequities that exist for women in the climate finance ecosystem and support female entrepreneurs with the resources they need to accelerate climate change innovations.

Amazon will commit a total of $53 million to help accelerate women’s climate solutions, including $3 million toward the USAID partnership and $50 million for Amazon to invest directly in climate tech companies run by women.

Amazon will serve as a founding partner of USAID’s Climate Gender Equity Fund, a new climate finance facility designed to remove systemic market barriers that prevent women and girls from accessing climate finance. USAID will also match Amazon’s $3 million investment to help launch the fund.

The Climate Gender Equity Fund will have a global focus and provide grants for businesses, NGOs, accelerators, incubators, and grassroots organizations working on women-led climate solutions. It also will fund efforts to help women access the networks and technical skills they need to accelerate the development of their climate change technologies.

As a co-founder of The Climate Pledge, a commitment to reach net-zero carbon emissions by 2040, Amazon will work with Pledge signatories and other companies to encourage their additional support and corporate investment in this new fund. The partnership will help advance mutual goals around women’s climate leadership and gender equity, including Amazon’s sustainability goals, the work of The Climate Pledge, and the Biden administration’s National Strategy on Gender Equity and Equality.

Additionally, Amazon is allocating $50 million from its Climate Pledge Fund to invest in women-founded and women-led climate tech companies, as well as incubators and accelerators that prioritize women-led entities. The Climate Pledge Fund–Amazon’s venture capital program that invests in companies pioneering decarbonizing technologies and solutions–will collaborate with USAID and the Climate Gender Equity Fund to source new investment opportunities and broaden its pipeline of female applicants.

“As an important step in solving climate change, we must address the gender inequalities that persist in climate finance, and ensure female entrepreneurs have an equal seat at the table and access to the funding, networks, and technical support they need to scale climate solutions,” said Kara Hurst, vice president of Worldwide Sustainability at Amazon. “We’re proud to collaborate with USAID and the Biden administration to help scale women-led climate solutions globally. This is just one part of our broader Climate Pledge goal to reach net-zero carbon by 2040, and we encourage other companies to join us in this effort.”

Female-founded companies typically receive a fraction of global venture capital, and that percentage fell during the pandemic. However, research shows that female entrepreneurs are more likely than their male counterparts to innovate to address social needs. Women-led companies also generate more revenue per dollar invested and produce greater ROI for investors.

Amazon has recently taken several additional steps to advance gender equality across its value chain, including:

  • Committing to the United Nations Women's Empowerment Principles (WEPs), which offer businesses guidance on ways to promote gender equity and empower women in the workplace, marketplace, and community.
  • Granting $1 million to the Resilience Fund for Women in Global Value Chains, which is investing in organizations supporting women in global value chains, including manufacturing, apparel, and agriculture, with a focus on gender-based violence and reproductive health.
  • Partnering with BSR’s HERproject to combat gender-based discrimination in China, Bangladesh, Vietnam, and India by engaging suppliers, factory workers, and management. These efforts have reached nearly 10,000 women.
  • Investing in the Elevate Future Fund, which increases funding to women and other underrepresented founders working on climate tech solutions, as well as firms creating economic opportunity for distressed and disadvantaged communities. This investment is part of the new Amazon Catalytic Capital initiative to provide underrepresented entrepreneurs with access to capital.
  • Collaborating with Greentown Labs, North America’s largest climate tech incubator, to source and engage with new startups. The Climate Pledge Fund participates in pitch events, including “Access to Success,” a community event for diverse founders. Amazon also serves on Greentown Labs’ Industry Leadership Council.
  • Working with Elemental Excelerator, a climate tech startup accelerator that is a leader in promoting diversity, equity, and inclusion principles in climate tech. Elemental Excelerator recently launched an Equity & Access program that helps startup founders build equity into their organizations’ teams and activities.

Learn more about Amazon’s sustainability efforts.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005180/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye